Antibody preparations from human transchromosomic cows exhibit prophylactic and therapeutic efficacy against Venezuelan equine encephalitis virus

Journal of Virology

Volumn 91, Issue 14, 2017, Pages

  Gardner, Christina L ^a   Sun, Chengqun ^a   Luke, Thomas ^b   Raviprakash, Kanakatte ^b   Wu, Hua ^c   Jiao, Jin an ^c   Sullivan, Eddie ^c   Reed, Douglas S ^a   Ryman, Kate D ^a   Klimstra, William B ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Department of Viral and Rickettsial Diseases ^*  (United States)

^c SAB Biotherapeutics   (United States)

Author keywords

Alphavirus; Passive immunotherapy; Transchromosomic bovine; Venezuelan equine encephalitis virus

Indexed keywords

PLASMID DNA; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG; VENEZUELAN EQUINE ENCEPHALITIS VIRUS IMMUNOGEN; VIRUS ANTIGEN; VIRUS VACCINE; VIRUS ANTIBODY;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNIZATION; MIXED INFECTION; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VENEZUELAN EQUINE ENCEPHALITIS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS INACTIVATION; VIRUS REPLICATION; ANIMAL; BOVINE; DISEASE MODEL; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; PASSIVE IMMUNIZATION; TRANSGENIC ANIMAL; TREATMENT OUTCOME;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIBODIES, VIRAL; CATTLE; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HUMANS; IMMUNIZATION, PASSIVE; MICE; TREATMENT OUTCOME;

EID: 85021219038     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00226-17     Document Type: Article

References (43)

1. Weaver SC, Powers AM, Brault AC, Barrett AD. 1999. Molecular epidemiological studies of veterinary arboviral encephalitides. Vet J 157:123-138. https://doi.org/10.1053/tvjl.1998.0289
2. Weaver SC, Ferro C, Barrera R, Boshell J, Navarro JC. 2004. Venezuelan equine encephalitis. Annu Rev Entomol 49:141-174. https://doi.org/10 .1146/annurev.ento.49.061802.123422
3. Johnson KM, Martin DH. 1974. Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18:79-116
4. Casadevall A, Pirofski LA. 2005. The potential of antibody-mediated immunity in the defence against biological weapons. Expert Opin Biol Ther 5:1359-1372. https://doi.org/10.1517/14712598.5.10.1359
5. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. 2010. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38:e66-e73. https://doi.org/10.1097/CCM .0b013e3181d44c1e
6. Dixit R, Herz J, Dalton R, Booy R. 2016. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens. Vaccine 34:1152-1161. https://doi.org/10 .1016/j.vaccine.2016.01.016
7. Casadevall A, Dadachova E, Pirofski LA. 2004. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695-703. https://doi.org/10 .1038/nrmicro974
8. Ahmadzadeh V, Farajnia S, Feizi MA, Nejad RA. 2014. Antibody humanization methods for development of therapeutic applications. Monoclon Antib Immunodiagn Immunother 33:67-73. https://doi.org/10.1089/mab.2013.0080
9. Sano A, Matsushita H, Wu H, Jiao JA, Kasinathan P, Sullivan EJ, Wang Z, Kuroiwa Y. 2013. Physiological level production of antigen-specific human immunoglobulin in cloned transchromosomic cattle. PLoS One 8:e78119. https://doi.org/10.1371/journal.pone.0078119
10. Kuroiwa Y, Kasinathan P, Sathiyaseelan T, Jiao JA, Matsushita H, Sathiyaseelan J, Wu H, Mellquist J, Hammitt M, Koster J, Kamoda S, Tachibana K, Ishida I, Robl JM. 2009. Antigen-specific human polyclonal antibodies from hyperimmunized cattle. Nat Biotechnol 27:173-181. https://doi .org/10.1038/nbt.1521
11. Matsushita H, Sano A, Wu H, Jiao JA, Kasinathan P, Sullivan EJ, Wang Z, Kuroiwa Y. 2014. Triple immunoglobulin gene knockout transchromosomic cattle: bovine lambda cluster deletion and its effect on fully human polyclonal antibody production. PLoS One 9:e90383. https://doi .org/10.1371/journal.pone.0090383
12. Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA. 2016. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Sci Rep 6:24897. https://doi.org/10.1038/srep24897
13. Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS. 2015. Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal Zaire and Sudan ebolaviruses. PLoS One 10:e0137786. https://doi.org/10.1371/journal.pone.0137786
14. Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, Glenn G, Flyer D, Defang G, Raviprakash K, Kochel T, Wang J, Nie W, Smith G, Hensley LE, Olinger GG, Kuhn JH, Holbrook MR, Johnson RF, Perlman S, Sullivan E, Frieman MB. 2016. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Transl Med 8:326ra21. https://doi .org/10.1126/scitranslmed.aaf1061
15. Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao JA, Matsushita H, Sullivan EJ. 2014. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci Transl Med 6:264ra162. https://doi.org/10.1126/scitranslmed.3010082
16. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. https://doi.org/10.1016/0003-2697(76)90527-3
17. Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, Blair CD. 2011. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 414:146-152. https://doi.org/10.1016/j.virol.2011.03.016
18. Goodchild SA, O'Brien LM, Steven J, Muller MR, Lanning OJ, Logue CH, D'Elia RV, Phillpotts RJ, Perkins SD. 2011. A humanised murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res 90: 1-8. https://doi.org/10.1016/j.antiviral.2011.01.010
19. Elvin SJ, Bennett AM, Phillpotts RJ. 2002. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J Med Virol 67:384-393. https://doi.org/10.1002/jmv.10086
20. Kaveri SV. 2012. Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev 11:792-794. https://doi.org/10 .1016/j.autrev.2012.02.006
21. Phillpotts RJ. 2006. Venezuelan equine encephalitis virus complexspecific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III. Virus Res 120:107-112. https://doi.org/10.1016/j.virusres.2006.02.003
22. O'Brien LM, Goodchild SA, Phillpotts RJ, Perkins SD. 2012. A humanised murine monoclonal antibody protects mice from Venezuelan equine encephalitis virus, Everglades virus and Mucambo virus when administered up to 48 h after airborne challenge. Virology 426:100-105. https://doi.org/10.1016/j.virol.2012.01.038
23. Fraenkel-Conrat H, Olcott HS. 1948. The reaction of formaldehyde with proteins; cross-linking between amino and primary amide or guanidyl groups. J Am Chem Soc 70:2673-2684. https://doi.org/10.1021/ja01188a018
24. Fraenkel-Conrat H, Olcott HS. 1948. Reaction of formaldehyde with proteins; cross-linking of amino groups with phenol, imidazole, or indole groups. J Biol Chem 174:827-843
25. Thavarajah R, Mudimbaimannar VK, Elizabeth J, Rao UK, Ranganathan K. 2012. Chemical and physical basics of routine formaldehyde fixation. J Oral Maxillofac Pathol 16:400-405. https://doi.org/10.4103/0973-029X .102496
26. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J, Gale MJ, Jr, Baric RS, Enjuanes L, Gallagher T, McCray PB, Jr, Perlman S. 2014. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A 111:4970-4975. https://doi.org/10 .1073/pnas.1323279111
27. Pratt WD, Gibbs P, Pitt ML, Schmaljohn AL. 1998. Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates. Vaccine 16:1056-1064. https://doi.org/10.1016/S0264-410X(97)00192-8
28. Reed DS, Lind CM, Sullivan LJ, Pratt WD, Parker MD. 2004. Aerosol infection of cynomolgus macaques with enzootic strains of Venezuelan equine encephalitis viruses. J Infect Dis 189:1013-1017. https://doi.org/10.1086/382281
29. Klein EY, Monteforte B, Gupta A, Jiang W, May L, Hsieh YH, Dugas A. 2016. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses 10:394-403. https://doi.org/10.1111/irv.12398
30. Lim FJ, de Klerk N, Blyth CC, Fathima P, Moore HC. 2016. Systematic review and meta-analysis of respiratory viral coinfections in children. Respirology 21:648-655. https://doi.org/10.1111/resp.12741
31. Munawwar A, Singh S. 2016. Human herpesviruses as copathogens of HIV infection, their role in HIV transmission, and disease progression. J Lab Physicians 8:5-18. https://doi.org/10.4103/0974-2727.176228
32. Coffey LL, Failloux AB, Weaver SC. 2014. Chikungunya virus-vector interactions. Viruses 6:4628-4663. https://doi.org/10.3390/v6114628
33. Davis NL, Willis LV, Smith JF, Johnston RE. 1989. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 171:189-204. https://doi .org/10.1016/0042-6822(89)90526-6
34. White LJ, Wang JG, Davis NL, Johnston RE. 2001. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5= untranslated region. J Virol 75: 3706-3718. https://doi.org/10.1128/JVI.75.8.3706-3718.2001
35. Sun C, Gardner CL, Watson AM, Ryman KD, Klimstra WB. 2014. Stable, high-level expression of reporter proteins from improved alphavirus expression vectors to track replication and dissemination during en-cephalitic and arthritogenic disease. J Virol 88:2035-2046. https://doi .org/10.1128/JVI.02990-13
36. MacDonald GH, Johnston RE. 2000. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74:914-922. https://doi.org/10.1128/JVI.74.2.914-922.2000
37. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401. https://doi.org/10.1006/viro.1997.8878
38. Gardner CL, Burke CW, Tesfay MZ, Glass PJ, Klimstra WB, Ryman KD. 2008. Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis. J Virol 82:10634-10646. https://doi.org/10 .1128/JVI.01323-08
39. Dupuy LC, Richards MJ, Ellefsen B, Chau L, Luxembourg A, Hannaman D, Livingston BD, Schmaljohn CS. 2011. A DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates. Clin Vaccine Immunol 18:707-716. https://doi.org/10.1128/CVI.00030-11
40. Garmashova N, Atasheva S, Kang W, Weaver SC, Frolova E, Frolov I. 2007. Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription. J Virol 81:13552-13565. https://doi.org/10.1128/JVI.01576-07
41. Garmashova N, Gorchakov R, Volkova E, Paessler S, Frolova E, Frolov I. 2007. The Old World and New World alphaviruses use different virusspecific proteins for induction of transcriptional shutoff. J Virol 81: 2472-2484. https://doi.org/10.1128/JVI.02073-06
42. Klimstra WB, Nangle EM, Smith MS, Yurochko AD, Ryman KD. 2003. DC-SIGN and L-SIGN can act as attachment receptors for alphaviruses and distinguish between mosquito cell-and mammalian cell-derived viruses. J Virol 77:12022-12032. https://doi.org/10.1128/JVI.77.22.12022-12032.2003
43. Reed DS, Xhillari D, Weiss AL, Jaeger RJ. 2016. Aerosol exposure to pathogenic bacteria and virus particles: standard operating procedure, p 445-459. In Salem H, Katz SA (ed), Aerobiology: the toxicology of airborne pathogens and toxins. The Royal Society of Chemistry, London, United Kingdom